GSKGlaxoSmithKlineRunning, no new patients
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Lung Cancer, Non-Small Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 351 (final count)
- Started
- Oct 14, 2022
- Main results expected
- Oct 26, 2026
- Fully finished
- Dec 6, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Measured over: Up to 228 weeks
Number of Participants with TEAEs or SAEs leading to dose modifications or treatment discontinuation
Measured over: Up to 228 weeks
Changes Tremor has spotted
Moved the main results date earlier: Nov 9, 2026 → Oct 26, 2026.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · date_moved_earlier · primary_completion_date
old: "2026-11-09"
new: "2026-10-26"
details: {"months":-0.5}
Trial ID NCT05565378 · record last updated 2026-11-09 · checked 2026-11-09 15:42 UTC